← Every company
Gilead Sciences, Inc Patents
What Gilead Sciences, Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
GILD on carbonthat →Filings on file
54
Granted
6
Still pending
48
Filed under
2 names
54 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| CAPSID INHIBITORS FOR THE TREATMENT OF HIVA61K 9/08, A61K 31/4427, A61K 31/4439, A61P 31/18, A61K 9/00, A61K 9/0019, A61K 9/0053, A61K 9/0095, A61K 9/2018, A61K 9/2054, A61K 9/4825, A61K 9/4858, A61K 31/34, A61K 31/4418, A61K 31/536, A61K 31/5365, A61K 31/685, A61K 45/06, A61K 47/02, A61K 47/10, A61K 47/14, A61K 47/26, A61K 47/34, A61K2300/00Filed as Gilead Sciences, Inc.2026-05-04Laura Elizabeth Bauer | pending |
| BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOFA61P 31/18, A61K 31/55, A61K 31/675, C07F 9/6561, A61K 31/4725, A61K 45/06, A61K2300/00, C07D 471/18, C07D 498/22Filed as Gilead Sciences, Inc.2026-05-01Megan K. Armstrong | pending |
| CAPSID INHIBITORS FOR THE PREVENTION OF HIVA61P 31/18, A61K 31/4439, C07D 401/14, A61K 9/0019, A61K 9/2054, A61K 31/454, A61K 31/553, A61K 31/675, A61K 45/06, A61K 47/10, A61K 47/34, A61K2300/00, C07B2200/13, C07D 401/12Filed as Gilead Sciences, Inc.2026-04-17Elena Bekerman | pending |
| SYSTEM AND METHOD FOR MULTI-LAYERED GRAPH INTEGRATION WITH DOMAIN-SPECIFIC AI AGENTS FOR DISPARATE DATA SOURCESFiled as GILEAD SCIENCES, INC.2026-03-25JENNIFER Z. ROZENBLIT | pending |
| PRE-S1 ANTIBODIES AND METHODS AND USES THEREOFFiled as GILEAD SCIENCES, INC.2026-03-16MEHRDAD MOSHREFI | pending |
| CAPSID INHIBITORS FOR THE TREATMENT OF HIVA61K 9/08, A61K 31/4427, A61K 31/4439, A61P 31/18, A61K 9/00, A61K 9/0019, A61K 9/0053, A61K 9/0095, A61K 9/2018, A61K 9/2054, A61K 9/4825, A61K 9/4858, A61K 31/34, A61K 31/4418, A61K 31/536, A61K 31/5365, A61K 31/685, A61K 45/06, A61K 47/02, A61K 47/10, A61K 47/14, A61K 47/26, A61K 47/34, A61K2300/00Filed as Gilead Sciences, Inc.2026-03-13Laura Elizabeth Bauer | pending |
| SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOFFiled as GILEAD SCIENCES, INC.2026-03-03ANA Z. GONZALEZ BUENROSTRO | pending |
| SOLID FORMS OF AN ALPHA4-BETA7 INTEGRIN ANTAGONIST AND COMPOUNDS THEREOFFiled as GILEAD SCIENCES, INC.2026-02-26KASSIBLA E. DEMPAH | pending |
| PROCESSES FOR PREPARING AN ALPHA4BETA7 INHIBITORFiled as GILEAD SCIENCES, INC.2026-02-26PETER A. BLOMGREN | pending |
| Pharmaceutical Formulations Comprising Tenofovir Alafenamide and EmtricitabineA61K 9/0053, A61K 9/2054, A61K 31/675, A61P 43/00, A61P 31/18, A61K 9/2013, A61K 9/209, A61K 9/284, A61K 9/2866, A61K 31/513, A61K2300/00Filed as Gilead Sciences, Inc.2026-02-20Joanna M. Koziara | 12678408 |
| ORAL TABLET FORMULATIONSFiled as GILEAD SCIENCES, INC.2026-02-19JAMES B. C. MACK | pending |
| COMBINATION THERAPY FOR TREATING HIVFiled as GILEAD SCIENCES, INC.2026-02-19JAMES B.C. MACK | pending |
| COMBINATION THERAPY FOR TREATING OR PREVENTING HIVFiled as GILEAD SCIENCES, INC.2026-02-19JAMES B.C. MACK | pending |
| COMPOSITIONS AND METHODS OF TREATMENTFiled as GILEAD SCIENCES, INC.2026-02-18ESHWARAN NARAYANAN | pending |
| BLISTER PACKFiled as Gilead Sciences, Inc.2026-02-17Robert Bridges | D1140740 |
| ANTI-CCR8 ANTIBODIES AND USES THEREOFFiled as GILEAD SCIENCES, INC.2026-02-06JILLIAN L. BOICE | pending |
| ANTI-CCR8 ANTIBODIES AND USES THEREOFC07K 16/2866, A61P 35/00, G01N2474/20, G01N 33/5758, C07K2317/20, C07K2317/33, C07K2317/34, C07K2317/565, C07K2317/567, C07K2317/92, C07K2317/94, G01N2333/7158Filed as Gilead Sciences, Inc.2026-02-06Jillian L. Boice | pending |
| PHARMACEUTICAL FORMULATIONS COMPRISING TENOFOVIR ALAFENAMIDE AND EMTRICITABINEA61K 9/0053, A61K 9/2054, A61K 31/675, A61P 43/00, A61P 31/18, A61K 9/2013, A61K 9/209, A61K 9/284, A61K 9/2866, A61K 31/513, A61K2300/00Filed as Gilead Sciences, Inc.2026-01-30Joanna M. Koziara | 12648911 |
| Pharmaceutical Formulations Comprising Tenofovir Alafenamide And EmtricitabineA61K 9/0053, A61K 9/2054, A61K 31/675, A61P 43/00, A61P 31/18, A61K 9/2013, A61K 9/209, A61K 9/284, A61K 9/2866, A61K 31/513, A61K2300/00Filed as Gilead Sciences, Inc.2026-01-27Joanna M. Koziara | 12661323 |
| CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDEC07F 9/65616, A61P 31/20, A61P 31/18, A61K 9/0019, A61K 31/675, A61K 45/06, C07B2200/13, C07C 55/20, C07C 65/11, C07C 309/35, C07D 239/557Filed as Gilead Sciences, Inc.2026-01-16Chiajen Lai | pending |
| PHARMACEUTICAL FORMULATIONS COMPRISING TENOFOVIR ALAFENAMIDE AND EMTRICITABINEA61K 9/0053, A61K 9/2054, A61K 31/675, A61P 43/00, A61P 31/18, A61K 9/2013, A61K 9/209, A61K 9/284, A61K 9/2866, A61K 31/513, A61K2300/00Filed as Gilead Sciences, Inc.2026-01-16Joanna M. Koziara | 12629338 |
| Pharmaceutical Formulations Comprising Tenofovir Alafenamide And EmtricitabineA61K 9/0053, A61K 9/2054, A61K 31/675, A61P 43/00, A61P 31/18, A61K 9/2013, A61K 9/209, A61K 9/284, A61K 9/2866, A61K 31/513, A61K2300/00Filed as Gilead Sciences, Inc.2026-01-16Joanna M. Koziara | pending |
| ANTIBODIES THAT BIND TO HUMAN CHEMOKINE (C-C MOTIF) RECEPTOR 8 (CCR8)C07K 16/2866, A61P 35/00, G01N 33/57505, A61K2039/505, C07K2317/24, C07K2317/41, C07K2317/51, C07K2317/515, C07K2317/52, C07K2317/56, C07K2317/565, C07K2317/732, C07K2317/734, C07K2317/76, C07K2317/92Filed as Gilead Sciences, Inc.2025-12-30Lara Lewis MCGRATH | 12729241 |
| CRYSTALLINE FORMS OF A PARP1 INHIBITORC07D 491/048, C07D 491/08, A61P 35/00, A61K 31/496Filed as Gilead Sciences, Inc.2025-12-22Jing Liu | pending |
| CRYSTALLINE FORMS OF A PARP1 INHIBITORFiled as GILEAD SCIENCES, INC.2025-12-22JING LIU | pending |
| CAPSID INHIBITORS FOR THE PREVENTION OF HIVFiled as Gilead Sciences, Inc.2025-12-22Elena Bekerman | pending |
| KRAS MODULATING COMPOUNDSFiled as GILEAD SCIENCES, INC.2025-12-19JULIE FARAND | pending |
| STAT6 COMPOUNDSC07D 401/14, C07D 471/10, A61P 37/06, A61K 31/454, A61K 31/4545, A61K 31/496, A61K 31/4985, A61K 31/4995, A61K 31/501, A61K 31/506, A61K 31/513, A61K 31/519, C07B 59/002, C07B2200/05, C07D 403/14, C07D 409/14, C07D 413/14, C07D 417/14, C07D 451/02, C07D 471/04, C07D 487/04, C07D 487/08, C07D 487/10Filed as Gilead Sciences, Inc.2025-12-18Alexander J. Burckle | pending |
| STAT6 COMPOUNDSFiled as GILEAD SCIENCES, INC.2025-12-18ALEXANDER J. BURCKLE | pending |
| COMBINATIONS FOR LIVER DISEASEA61K 31/192, A61P 43/00, A61P 1/16, A61P 29/00, A61P 17/04, A61K 31/235, A61K 31/415, A61K 31/42, A61K 31/4436, A61K 31/4439, A61K 31/454, A61K 31/46, A61K 31/496, A61K 31/575, A61K 45/06, A61K2300/00Filed as Gilead Sciences, Inc.2025-12-17Yun-Jung Choi | pending |
| PARP7 INHIBITORSFiled as GILEAD SCIENCES, INC.2025-12-17JONAH J. CHANG | pending |
| COMBINATIONS FOR LIVER DISEASEFiled as GILEAD SCIENCES, INC.2025-12-17YUN-JUNG CHOI | pending |
| PARP7 INHIBITORSC07D 471/00, C07F 9/65583, A61P 35/00, A61K 31/506, A61K 31/675, C07D 401/14Filed as Gilead Sciences, Inc.2025-12-17Jonah J. Chang | pending |
| ANTIVIRAL INDOLINYL COMPOUNDS AND USES THEREOFC07D 401/10, A61P 31/22, A61P 31/12, A61K 31/404, A61K 31/4439, A61K 45/06, C07D 209/08, C07D 209/12, C07D 403/10, C07D 405/06, C07D 405/14, C07D 413/10, C07D 417/02, C07D 417/10Filed as Gilead Sciences, Inc.2025-12-11Aesop CHO | pending |
| ORAL TABLET FORMULATIONSA61K 9/2018, A61K 31/675, A61P 31/18, A61K 9/2027, A61K 9/2054Filed as Gilead Sciences, Inc.2025-12-09Melissa A. King | pending |
| METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONSA61K 31/675, A61P 31/18, A61K 9/2018, A61K 9/2027, A61K 9/2031, A61K 9/2054, A61K 31/55, A61K2300/00Filed as Gilead Sciences, Inc.2025-12-08Ana Z. Gonzalez Buenrostro | pending |
| METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONSFiled as GILEAD SCIENCES, INC.2025-12-08ANA Z. GONZALEZ BUENROSTRO | pending |
| MODIFIED INTERNAL RIBOSOME ENTRY SITE (IRES) ELEMENTS AND METHODS OF USEFiled as GILEAD SCIENCES, INC.2025-11-20BO JIANG | pending |
| MODIFIED INTERNAL RIBOSOME ENTRY SITE (IRES) ELEMENTS AND METHODS OF USEC12N 15/67, C12N 15/85, C07K 14/52, C07K 16/00, C07K2317/31, C07K2317/55, C07K2317/569, C07K2319/30, C12N2830/50, C12N2840/203Filed as Gilead Sciences, Inc.2025-11-20Bo Jiang | pending |
| SINGLE IMMUNOGLOBULIN DOMAIN BISPECIFIC ANTIBODIES AGAINST IL 10R alpha AND beta SUBUNITS AND METHODS OF USEA61P 37/00, C07K 16/2866, A61P 19/02, A61P 29/00, A61K2039/505, A61K2039/545, C07K2317/22, C07K2317/24, C07K2317/31, C07K2317/34, C07K2317/52, C07K2317/565, C07K2317/567, C07K2317/569, C07K2317/73, C07K2317/75, C07K2317/90, C07K2317/92, C07K2317/94Filed as Gilead Sciences, Inc.2025-11-20Chen Chen | pending |
| SINGLE IMMUNOGLOBULIN DOMAIN BISPECIFIC ANTIBODIES AGAINST IL-10R ALPHA AND BETA SUBUNITS AND METHODS OF USEFiled as GILEAD SCIENCES, INC.2025-11-20CHEN CHEN | pending |
| SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASESC07D 401/14, C07D 487/04, C07D 401/04, C07D 401/12, C07D 403/12, C07D 403/14, C07D 405/14, C07D 413/14, C07D 417/14, C07D 471/04, C07D 495/04, C07D 519/00Filed as Gilead Sciences, Inc.2025-11-17Wylie Palmer | pending |
| CRYSTALLINE FORMS OF AN AZETIDINE PARP1 INHIBITORFiled as GILEAD SCIENCES, INC.2025-11-12BING SHI | pending |
| CRYSTALLINE FORMS OF AN AZETIDINE PARP1 INHIBITORC07D 471/04, A61P 35/00, C07B2200/13, C07C 59/255Filed as Gilead Sciences, Inc.2025-11-12Bing Shi | pending |
| PHARMACEUTICAL FORMULATIONS OF BICTEGRAVIR AND LENACAPAVIRA61K 9/2054, A61K 9/2086, A61K 9/209, A61P 31/18, A61K 9/2018, A61K 9/2031, A61K 9/2095, A61K 31/4439, A61K 31/553, A61K2300/00Filed as Gilead Sciences, Inc.2025-11-07Priyanka Arora | pending |
| TETRACYCLIC COMPOUNDS AND METHODS FOR THE TREATMENT OF ZIKA VIRUS INFECTIONA61P 31/14, C07D 493/06, Y02A 50/30, A61K 31/4178Filed as Gilead Sciences, Inc.2025-10-29Elbert Chin | pending |
| STAT6 COMPOUNDSFiled as Gilead Sciences, Inc.2025-10-24Alexander J. Burckle | pending |
| LPA RECEPTOR ANTAGONISTS AND USES THEREOFC07D 401/14, A61P 43/00, A61P 1/16, A61P 9/00, A61P 13/12, A61P 11/00, A61P 29/00, A61P 35/00, A61K 31/232, A61K 31/4439, A61K 31/444, A61K 31/506, A61K 31/519, A61K 31/5377, A61K 38/179, A61K 45/06, C07D 405/14, C07D 413/14, C07D 417/14, A61K2300/00Filed as Gilead Sciences, Inc.2025-10-24Brian P. Bestvater | pending |
| HIV INHIBITOR COMPOUNDSA61K 31/52, C07D 487/08, A61P 31/18, A61K 31/4995, A61K 31/5386, A61K 31/55, A61K 31/553, A61K 31/685, A61K 31/688, A61K 45/06, C07C 243/28, C07C 275/16, C07D 401/12, C07D 403/12, C07D 405/14, C07D 471/08, C07D 487/10, C07D 491/04, C07D 491/107, C07D 498/04, C07D 498/08, C07D 519/00Filed as Gilead Sciences, Inc.2025-10-22Elizabeth M. Bacon | pending |
| CD4-TARGETED IL-15 MOLECULES AND METHODS OF USEFiled as GILEAD SCIENCES, INC.2025-10-21MANUEL BACA | pending |
| CD4-TARGETED IL-15 MOLECULES AND METHODS OF USEC07K 14/5443, C07K 14/7155, A61K 47/6849, A61K 47/6813, A61P 31/18, A61P 35/00, A61K 38/00, C07K 16/2812, C07K2317/34, C07K2317/52, C07K2317/565, C07K2317/92, C07K2319/00, C07K2319/03, C07K2319/30, C07K2319/33, C07K2319/70Filed as Gilead Sciences, Inc.2025-10-21Manuel Baca | pending |
| PRMT5 INHIBITORS AND USES THEREOFFiled as GILEAD SCIENCES, INC.2025-10-17LAURENT P. DEBIEN | pending |
| PRMT5 INHIBITORS AND USES THEREOFA61K 31/437, C07D 491/16, A61K 31/5386, C07D 519/00Filed as Gilead Sciences, Inc.2025-10-17Laurent P. Debien | pending |
| KRAS MODULATING COMPOUNDSC07D 498/22, A61P 35/00, A61K 31/553, C07D 519/00Filed as Gilead Sciences, Inc.2025-10-09Eda Y. Canales | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on GILD
Company overviewEverything on GILD in one place, with the price.SEC filingsWhat GILD's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat GILD's own officers and directors buy and sell.Planned salesSales GILD insiders have filed notice of.Who owns itEvery manager reporting a position in GILD.Funds holding itWhich funds and ETFs hold GILD, and how big a bet.LobbyingWhat GILD spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on GILD's account, and who they worked for.Federal contractsWhat federal agencies pay GILD.